NUP62CL: A Potential Drug Target and Biomarker (G54830)

Target Name: NUP62CL

NCBI ID: G54830

NUP62CL

NUP62CL: A Potential Drug Target and Biomarker

NUP62CL is a novel gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. NUP62CL is a non-coding RNA molecule that has been shown to play a critical role in the regulation of cellular processes, including cell adhesion, migration, and survival.

The NUP62CL gene was first identified using RNA sequencing techniques and has been shown to encode a protein that is expressed in various tissues and organs, including brain, heart, liver, and muscle. The protein produced by the NUP62CL gene has been shown to have unique functions in regulating cell adhesion and survival, and is thought to be involved in the development and progression of various diseases.

One of the key functions of NUP62CL is its role in cell adhesion. NUP62CL has been shown to play a critical role in the regulation of tight junctions, which are critical for maintaining the integrity of the blood-brain barrier and for ensuring the proper delivery of therapeutic agents to brain cells. The NUP62CL protein has been shown to interact with several different proteins, including E-cadherin, a protein that is known to be involved in cell adhesion and has been shown to be a potential drug target for various diseases, including cancer.

Another function of NUP62CL is its role in cell survival. NUP62CL has been shown to play a critical role in the regulation of cellular apoptosis, which is the process by which cells die when they have reached their lifespan. The NUP62CL protein has been shown to be involved in the regulation of apoptosis, and has been shown to play a positive role in the development of neurodegenerative diseases.

In addition to its role in cell adhesion and survival, NUP62CL has also been shown to play a critical role in the regulation of cellular processes that are involved in the development and progression of various diseases. For example, NUP62CL has been shown to play a positive role in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. This is thought to contribute to the development of diseases such as cancer, where the growth and development of new blood vessels is often a key factor.

Given the unique functions of NUP62CL as a protein, it is a promising candidate for drug targeting and biomarker development. The NUP62CL gene has been shown to be involved in the regulation of various cellular processes that are involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, NUP62CL may be a valuable drug target and biomarker for these diseases.

In conclusion, NUP62CL is a novel gene that has been identified as a potential drug target and biomarker for various diseases. The NUP62CL protein has been shown to play a critical role in the regulation of cell adhesion, survival, and angiogenesis, and is therefore a promising candidate for drug targeting and biomarker development. Further research is needed to fully understand the functions of NUP62CL and its potential as a drug target and biomarker.

Protein Name: Nucleoporin 62 C-terminal Like

The "NUP62CL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUP62CL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets